Overview
US biopharmaceutical firm's Q1 loss was smaller than expected
Company ended Q1 with $730 mln in cash, funding runway into 2029
Outlook
Company says current cash position expected to fund operations into 2029
Result Drivers
PIPELINE ADVANCEMENT - Higher R&D expenses driven by progress in bitopertin clinical studies, advancement of DISC-0974 and DISC-3405 programs, and increased headcount
COMMERCIALIZATION PREPARATION - SG&A expenses rose due to increased headcount and building infrastructure to support potential commercialization
Company press release: ID:nGNX9RCSDR
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$63.50 mln
-$67.08 mln (6 Analysts)
Q1 Basic EPS
Beat
-$1.65
-$1.71 (10 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 47.8% above its May 4 closing price of $67.64
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
